Early initiation of sodium‐glucose linked transporter inhibitors (SGLT‐2i) and associated metabolic and electrolyte outcomes in diabetic kidney transplant recipients
Abstract There is a paucity of data on the use of SGLT2 inhibitors on outcomes in kidney transplant recipients. There may be concern in initiating these agents, especially within the first year post‐transplant when renal function is more labile and immunosuppression more intense, due to a presumed h...
Main Authors: | Chelsey Chenxi Song, Andrew Brown, Ryan Winstead, Idris Yakubu, Moses Demehin, Dhiren Kumar, Gaurav Gupta |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-04-01
|
Series: | Endocrinology, Diabetes & Metabolism |
Online Access: | https://doi.org/10.1002/edm2.185 |
Similar Items
-
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibition in Kidney Transplant Recipients with Diabetes Mellitus
by: Moritz Mahling, et al.
Published: (2019-08-01) -
Effect of Remdesivir on COVID-19 PCR Positivity and Cycle Threshold in Kidney Transplant Recipients
by: Ryan J. Winstead, et al.
Published: (2021-08-01) -
POS-780 SODIUM-GLUCOSE CO-TRANSPORTER 2 INHIBITORS (SGLT2i) SHORT-TERM OUTCOME IN DIABETIC KIDNEY TRANSPLANT RECIPIENTS
by: J. Yagan, et al.
Published: (2021-04-01) -
Sodium glucose transporter 2 (SGLT2) inhibition and ketogenesis
by: Sanjay Kalra, et al.
Published: (2015-01-01) -
COVID-19 in Kidney Transplantation: Epidemiology, Management Considerations, and the Impact on Kidney Transplant Practice
by: Ashish Kataria, MD, et al.
Published: (2020-08-01)